RxDoctor Payments Data

Brandy Miles, PA

Medical · Pensacola, FLNPI 1760664817

Payments from drug & device makers

$10,199in general payments, 2019–2025

Across 500 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • Inspire Medical Systems, Inc.$982
  • Actelion Pharmaceuticals US, Inc.$617
  • Regeneron Healthcare Solutions, Inc.$540
  • plus $4K from 34 others

What the payments were for

  • Travel & lodging$8168%
  • Food & beverage$9,38392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,199 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$37,867
Medicare patients
306
Services billed
434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter206$147,373
Breztri AerosphereBudesonide/Glycopyr/Formoterol53$33,125
Spiriva RespimatTiotropium Bromide49$29,818
Breo ElliptaFluticasone/Vilanterol60$27,653
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$12,165
SymbicortBudesonide/Formoterol Fumarate34$11,272
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$9,812
Incruse ElliptaUmeclidinium Bromide14$6,963
Albuterol Sulfate HfaAlbuterol Sulfate194$5,475
Advair HfaFluticasone Propion/Salmeterol12$4,623
Ventolin HfaAlbuterol Sulfate40$3,090
Fluticasone Propionate42$936
Ipratropium Bromide14$530
Montelukast Sodium26$405
Omeprazole16$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,257$191,801294 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,564$44,39787 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,069$41,98364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.

Other medical in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →